25.43
price up icon1.56%   0.39
after-market 시간 외 거래: 25.08 -0.35 -1.38%
loading
전일 마감가:
$25.04
열려 있는:
$25.15
하루 거래량:
756.48K
Relative Volume:
1.17
시가총액:
$1.80B
수익:
$80.89M
순이익/손실:
$-144.73M
주가수익비율:
-8.5623
EPS:
-2.97
순현금흐름:
$-83.87M
1주 성능:
+0.91%
1개월 성능:
+14.55%
6개월 성능:
+98.98%
1년 성능:
+293.65%
1일 변동 폭
Value
$23.89
$25.46
1주일 범위
Value
$23.51
$25.46
52주 변동 폭
Value
$4.96
$27.60

누릭스 테라퓨틱스 Stock (NRIX) Company Profile

Name
명칭
Nurix Therapeutics Inc
Name
전화
(415) 660-5320
Name
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
직원
284
Name
트위터
Name
다음 수익 날짜
2024-10-14
Name
최신 SEC 제출 서류
Name
NRIX's Discussions on Twitter

누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-07-31 개시 Truist Buy
2023-06-26 재개 Oppenheimer Outperform
2023-03-09 개시 Barclays Overweight
2023-02-28 개시 Oppenheimer Outperform
2022-10-11 개시 Morgan Stanley Equal-Weight
2022-05-31 업그레이드 Wells Fargo Equal Weight → Overweight
2022-02-10 개시 Wells Fargo Equal Weight
2021-12-29 개시 H.C. Wainwright Buy
2021-10-14 개시 SVB Leerink Outperform
2021-06-04 재개 Robert W. Baird Outperform
2021-04-30 재개 Piper Sandler Overweight
2021-04-30 개시 RBC Capital Mkts Outperform
2021-04-14 개시 Berenberg Buy
2020-11-19 개시 Robert W. Baird Outperform
2020-08-18 개시 JP Morgan Overweight
2020-08-18 개시 Needham Buy
2020-08-18 개시 Piper Sandler Overweight
2020-08-18 개시 Stifel Buy
모두보기

누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스

pulisher
09:17 AM

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

09:17 AM
pulisher
Nov 04, 2024

Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com

Nov 04, 2024
pulisher
Nov 03, 2024

(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India

Nov 02, 2024
pulisher
Nov 02, 2024

Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St

Oct 31, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia

Oct 30, 2024
pulisher
Oct 30, 2024

Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada

Oct 26, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

UBS sees upside for Nurix stock driven by promising NX-5948 data in CLL/SLL - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

UBS Group Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

What is HC Wainwright’s Forecast for NRIX FY2024 Earnings? - Defense World

Oct 24, 2024
pulisher
Oct 23, 2024

(NRIX) On The My Stocks Page - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 23, 2024

HC Wainwright Has Bullish Estimate for NRIX FY2024 Earnings - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World

Oct 23, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial - Clinical Trials Arena

Oct 21, 2024
pulisher
Oct 20, 2024

WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 20, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the - GlobeNewswire

Oct 19, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia - Yahoo Finance

Oct 19, 2024
pulisher
Oct 19, 2024

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - The Manila Times

Oct 19, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics stock soars to 52-week high of $26.31 By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics (NASDAQ:NRIX) Reaches New 52-Week HighHere's What Happened - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Nurix Therapeutics stock soars to 52-week high of $26.31 - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

The Manufacturers Life Insurance Company Purchases 4,583 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics adds pharma veteran Anil Kapur to board - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics adds pharma veteran Anil Kapur to board By Investing.com - Investing.com South Africa

Oct 16, 2024
pulisher
Oct 16, 2024

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Take off with Nurix Therapeutics Inc (NRIX): Get ready for trading - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - Defense World

Oct 16, 2024

누릭스 테라퓨틱스 (NRIX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Ring Christine
Chief Legal Officer
Nov 04 '24
Sale
25.00
3,290
82,250
28,084
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):